J Refract Surg. 2025 Feb;41(2):e102-e113. doi: 10.3928/1081597X-20241113-01. Epub 2025 Feb 1.
ABSTRACT
PURPOSE: To compare clinical outcomes for patients implanted with either FineVision HP or FineVision Triumf intraocular lenses (IOL) (Beaver-Visitec International, Inc) following cataract surgery.
METHODS: Twenty-six patients bilaterally implanted with the HP IOL and 27 patients with the Triumf IOL were followed up for 6 months in a prospective randomized study. Refraction, uncorrected and corrected distance visual acuity (CDVA), uncorrected and distance-corrected intermediate visual acuity (DCIVA), and uncorrected and distance-corrected near visual acuity (DCNVA) were evaluated. Defocus curves and contrast sensitivity were also measured. Patient-reported outcomes were assessed using the National Eye Institute Visual Function Questionnaire 25, and adverse events were registered.
RESULTS: Ninety-four percent of the eyes in both groups were within ±1.00 diopter (D) of spherical equivalent. All of the patients had 20/20 or better binocular CDVA in both groups and 96% and 100% had 20/25 or better binocular CDIVA in the Triumf and HP IOL groups, respectively, being reduced to 32% and 91.7% for DCNVA, respectively. Differences between groups were statistically significant from -2.00 to -4.50 D with better visual acuity outcomes for the HP IOL group (P < .01). Better monocular photopic contrast sensitivity was found for the Triumf IOL group at 12 and 18 cycles per degree (P < .01). There was a statistically significant increase of the overall composite score in both groups before and after surgery (P < .001). Spectacle independence was similar between groups for distance and intermediate vision but higher for the HP IOL for near vision (96% versus 75%). There were no adverse events related to the IOLs.
CONCLUSIONS: Both IOLs showed good and comparable distance and intermediate visual acuities but near vision was better for the HP IOL. This model provided higher spectacle independence for near vision. [J Refract Surg. 2025;41(3):e102-e113.].
PMID:39937980 | DOI:10.3928/1081597X-20241113-01